| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The targets of NVOC cage-TMP-Halo are HaloTag fusion proteins and the TMP-binding protein. The NVOC group acts as a photocage that prevents the TMP ligand from binding to its target. Upon exposure to light (typically UV), the NVOC group is cleaved (uncaged), releasing the active TMP ligand. This allows for rapid, reversible, and spatially controlled manipulation of protein localization in living cells.
|
|---|---|
| ln Vitro |
The capacity to precisely control protein distribution in HeLa cells spatially using NVOC cage-TMP-Halo (20μM, 15, 30, and 60 minutes) [1]. In HeLa cells expressing CENPB-GFP-Haloenzyme and mCherry-eDHFR, NVOC cage-TMP-Halo (20μM, 60 min) strongly recruits mCherry-eDHFR to centromeres at a rate of t1/2 of roughly 15 s[1].
In vitro, NVOC cage-TMP-Halo enables rapid, reversible, and spatially controlled manipulation of protein localization in living cells. Upon photoactivation, it induces protein dimerization, allowing for the study of dynamic cellular processes, signal transduction, and real-time protein function with high temporal precision. It is used as a powerful optochemical tool for studying dynamic cellular processes. |
| ln Vivo |
In vivo studies of NVOC cage-TMP-Halo are not typically conducted as it is a cell-permeable tool used in cell culture systems. It is designed for use in living cells, not in whole organisms. Its application is limited to in vitro cell-based studies for optogenetics and chemical biology research.
|
| Enzyme Assay |
No specific protocols for enzyme/receptor binding assays are available for NVOC cage-TMP-Halo as it is a photoactivatable tool compound. Standard assays involve treating cells expressing HaloTag fusion proteins with the compound, followed by light activation to induce protein dimerization. Protein localization is monitored by fluorescence microscopy. The efficacy of photoactivation can be assessed by measuring the extent of protein dimerization or translocation.
|
| Cell Assay |
Cellular assays for NVOC cage-TMP-Halo involve treating cells expressing HaloTag fusion proteins with the compound at concentrations ranging from 1-100 µM for 15-60 minutes. After washing, cells are exposed to UV light (typically 365 nm) to photoactivate the compound. Protein localization is monitored by fluorescence microscopy or live-cell imaging. The kinetics of protein dimerization and dissociation can be measured. These cell-based systems allow for high spatiotemporal control of protein function.
|
| Animal Protocol |
In vivo animal experiments for NVOC cage-TMP-Halo are not conducted as it is a cell-permeable tool used in cell culture systems. It is not intended for use in whole organisms. Its application is limited to in vitro cell-based studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for NVOC cage-TMP-Halo are not relevant as it is a research tool, not a therapeutic agent. It is used in cell culture and is not intended for systemic administration. No PK studies have been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for NVOC cage-TMP-Halo are limited. As a research tool, it is used in small quantities in laboratory settings. Standard laboratory safety precautions should be followed when handling the compound. It is intended for research use only.
|
| References |
[1]. Ballister ER, et al. Localized light-induced protein dimerization in living cells using a photocaged dimerizer. Nat Commun. 2014 Nov 17;5:5475.
|
| Additional Infomation |
NVOC cage-TMP-Halo is a cell-permeable, photoactivatable chemical inducer of dimerization (CID) composed of a TMP ligand, an NVOC photocage, and a HaloTag-reactive moiety. It enables rapid, reversible, and spatially controlled manipulation of protein localization in living cells upon light activation. It is used in optogenetics, chemical biology, and dynamic protein studies. It is a research tool and is not approved for any clinical indication.
|
| Molecular Formula |
C40H56CLN7O13
|
|---|---|
| Molecular Weight |
878.364749908447
|
| Exact Mass |
877.362
|
| CAS # |
2137894-98-3
|
| PubChem CID |
85470616
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
30
|
| Heavy Atom Count |
61
|
| Complexity |
1250
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClCCCCCCOCCOCCNC(CCC(NCCCOC1C(=CC(=CC=1OC)CC1=CN=C(NC(=O)OCC2C=C(C(=CC=2[N+](=O)[O-])OC)OC)N=C1N)OC)=O)=O
|
| InChi Key |
DUNVDVWPSITHRB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C40H56ClN7O13/c1-54-31-23-29(30(48(52)53)24-32(31)55-2)26-61-40(51)47-39-45-25-28(38(42)46-39)20-27-21-33(56-3)37(34(22-27)57-4)60-16-9-13-43-35(49)10-11-36(50)44-14-17-59-19-18-58-15-8-6-5-7-12-41/h21-25H,5-20,26H2,1-4H3,(H,43,49)(H,44,50)(H3,42,45,46,47,51)
|
| Chemical Name |
(4,5-dimethoxy-2-nitrophenyl)methyl N-[4-amino-5-[[4-[3-[[4-[2-[2-(6-chlorohexoxy)ethoxy]ethylamino]-4-oxobutanoyl]amino]propoxy]-3,5-dimethoxyphenyl]methyl]pyrimidin-2-yl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1385 mL | 5.6924 mL | 11.3849 mL | |
| 5 mM | 0.2277 mL | 1.1385 mL | 2.2770 mL | |
| 10 mM | 0.1138 mL | 0.5692 mL | 1.1385 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
